Terry Friedlander
@DrTFriedlander
Followers
254
Following
4
Media
10
Statuses
15
Professor of Medicine at UCSF, Robert and Virginia O’Reilly Endowed Chair, and Chief, ZSFG Division of Hematology & Oncology
San Francisco, CA
Joined October 2009
1
5
37
Long awaited combination of Sacituzumab plus Immunotherapy in the JCO. Congrats to Dr Grivas @PGrivasMDPhD all the authors. https://t.co/D4RfrNb5MZ
pubmed.ncbi.nlm.nih.gov
SG plus pembrolizumab demonstrated a high response rate with an overall manageable toxicity profile in patients with mUC who progressed after platinum-based chemotherapy. No new safety signals were...
0
2
10
Great talk today by Kala Sridhar @kalasri3 at #ESMOAsia2023 on the current landscape in bladder cancer. So many new developments in such a short time!
0
2
16
Great start to Uromigos Live meeting. Lots to discuss in frontline mUC space. All star pane here! #UromigosLive 2023
0
5
9
So excited to to finally see our trial of combining check point inhibitors (pembrolizumab) with a single dose of 177Lu-PSMA-617 finally get published in @TheLancetOncol. Great team work @UCSFCancer. Amazing PSA50 (56%) and duration of response with a single dose of RLT!
10
32
132
Concluding another amazing @PCFnews @PCF_Science retreat with lots of great science and celebration of 2023 class of Young Investigators @UCSFCancer @UCSFUrology @HemoncUcsf @xiaolin_zhu @Bajji @AlanBryce9 @PBarataMD @RohitBoseMDPhD @charlesryanmd @AndreaMiyahira @soulehoward1
The PCF Young Investigator Awards nurture and grow the future leaders in the field of #prostatecancer research. They bring new ideas, new energy, and impact the prostate cancer field in innovative ways. 🔬Congratulations again 2023 Young Investigators! https://t.co/lGy17OGEe7
0
9
25
Discussing LITESPARK-005 trial. Some patients getting good responses (22.5% PR, 3.5% CR rates) and durable PFS with #belzutifan in late line, TKI-pretreated pts. @maughanonc @_CurioScience_ #RCC
1
2
10
Latest updates in RCC with my good friend Dr Benjamin Maughan @maughanonc . Exciting data with belzutifan and new TKI / IO combos!#kidneycancer @_CurioScience_ @Huntsman_GU
0
6
16
Listening to a great talk reviewing what’s new in urothelial cancer by my good friend and colleague Dr Petros Grivas @PGrivasMDPhD #curioscience #bladdercancer
0
5
25
Amazing results of EV-302 trial yesterday, significant improvements in OS, PFS, ORR and CR rates. Over half of control arm pts got PD1 therapies, including 30% use of maintenance avelumab, making this an apt really world comparison. #ESMO2023 #bladdercancer #enfortumab
0
6
26
Update on the EV-103 study. Thanks to all the of participants and their families. https://t.co/Mte6NAkvRl
ecancer.org
Dr Terence Friedlander talks to ecancer about the updates in the EV-103 study focusing on durability results of enfortumab vedotin + pembrolizumab in first l
0
0
2